SCNLF Stock - Scancell Holdings plc
Unlock GoAI Insights for SCNLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.71M | $5.27M | $5.27M | N/A | N/A |
| Gross Profit | $4.47M | $4.75M | $4.75M | $-740,000 | $-249,000 |
| Gross Margin | 94.9% | 90.0% | 90.0% | N/A | N/A |
| Operating Income | $-15,001,000 | $-11,920,000 | $-11,920,000 | $-13,299,000 | $-8,834,000 |
| Net Income | $-12,272,000 | $-11,936,000 | $-11,936,000 | $-2,065,000 | $-15,477,000 |
| Net Margin | -260.5% | -226.4% | -226.4% | N/A | N/A |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Visit WebsiteEarnings History & Surprises
SCNLFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 24, 2025 | — | — | — | — |
Q1 2025 | Jan 28, 2025 | — | $-0.02 | — | — |
Q3 2024 | Sep 24, 2024 | — | $-0.00 | — | — |
Q1 2024 | Jan 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Jan 25, 2023 | — | $-0.00 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.01 | — | — |
Q4 2021 | Oct 29, 2021 | — | $0.01 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.02 | — | — |
Q1 2021 | Jan 29, 2021 | — | $-0.01 | — | — |
Q2 2020 | Apr 30, 2020 | — | $-0.01 | — | — |
Q1 2020 | Jan 31, 2020 | — | $-0.01 | — | — |
Q3 2019 | Aug 20, 2019 | — | $-0.01 | — | — |
Q1 2019 | Jan 31, 2019 | — | $-0.01 | — | — |
Q3 2018 | Sep 25, 2018 | — | $-0.01 | — | — |
Q1 2018 | Jan 30, 2018 | — | $-0.01 | — | — |
Q3 2017 | Sep 13, 2017 | — | $-0.01 | — | — |
Q1 2017 | Mar 24, 2017 | — | $-0.01 | — | — |
Q3 2016 | Sep 16, 2016 | — | $-0.01 | — | — |
Q4 2015 | Oct 31, 2015 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about SCNLF
What is SCNLF's current stock price?
What is the analyst price target for SCNLF?
What sector is Scancell Holdings plc in?
What is SCNLF's market cap?
Does SCNLF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SCNLF for comparison